Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma.

Cancer shared this article with you from Inoreader Somatic Epigenetic Silencing of RIPK3 Inactivates Necroptosis and Contributes to Chemoresistance in Malignant Mesothelioma. Via Clinical Cancer Research CONCLUSIONS: These data suggest that RIPK3 acts as a tumor suppressor in MM by triggering necroptosis and that epigenetic silencing of RIPK3 by DNA methylation impairs necroptosis and contributes to chemoresistance and poor survival in this incurable disease. PMID: 33203643 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research) View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.